SMARCA2 is altered in 2.56% of breast carcinoma patients [3].

SMARCA2 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is altered in 2.5% of endometrial endometrioid adenocarcinoma patients [3].

SMARCA2 is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is altered in 3.33% of malignant solid tumor patients [3].

SMARCA2 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

SMARCA2 is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains SMARCA2 status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].